PharmaRoth Labs, Inc. (ROTH) Stock Analysis

PharmaRoth Labs, Inc. (ROTH) Healthcare & Pipeline Overview

PharmaRoth Labs, Inc. is a nutraceutical company specializing in herbal-based treatments for type-2 diabetes, primarily through its Sucanon product. Operating globally from its Las Vegas headquarters, the company faces competition in the biotechnology sector while addressing a significant market need.

What Is the Investment Thesis for ROTH?

PharmaRoth Labs, Inc. presents a focused investment opportunity within the nutraceutical market, specifically targeting type-2 diabetes with its Sucanon product. The company's gross margin of 40.2% indicates potential profitability, but its negative profit margin of -278.6% raises concerns about operational efficiency and cost management. Key value drivers include expanding Sucanon's market share and achieving regulatory approvals in new geographic regions. Growth catalysts involve strategic partnerships and further clinical validation of Sucanon's efficacy. Potential risks include competition from established pharmaceutical companies and the evolving regulatory landscape for nutraceuticals. Investors should closely monitor the company's ability to improve its profit margins and demonstrate sustained revenue growth.

Based on FMP financials and quantitative analysis

ROTH Key Highlights

PharmaRoth Labs, Inc. focuses on the nutraceutical market, specifically targeting type-2 diabetes with its Sucanon product.

• The company's gross margin stands at 40.2%, indicating potential profitability from its core product.
• PharmaRoth Labs, Inc. rebranded from Fero Industries Inc. in March 2013, signaling a strategic shift towards the nutraceutical market.
• The company's negative profit margin of -278.6% raises concerns about operational efficiency and cost management.
• PharmaRoth Labs, Inc. has a beta of 0.38, suggesting lower volatility compared to the overall market.

Who Are ROTH's Competitors?

ROTH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ROTH's Key Strengths?

Focus on herbal-based nutraceutical treatments.

• Proprietary formulation of Sucanon.
• Established presence in certain markets.
• Gross margin of 40.2%.

What Are ROTH's Weaknesses?

Negative profit margin of -278.6%.

• Limited product portfolio.
• Dependence on Sucanon for revenue.
• Small market capitalization.

What Could Drive ROTH Stock Higher?

Regulatory approvals for Sucanon in new geographic regions (e.g., Europe, Asia).

• Strategic partnerships with healthcare providers and distributors.
• Clinical trials to validate the efficacy of Sucanon.

What Are the Key Risks for ROTH?

Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.

• Competition from established pharmaceutical companies and other nutraceutical firms.
• Evolving regulatory landscape for nutraceutical products.
• Adverse effects of Sucanon.
• Negative profit margin and operational inefficiencies.

What Are the Growth Opportunities for ROTH?

• Expanding Market Reach for Sucanon: PharmaRoth Labs, Inc. has the opportunity to expand the market reach of Sucanon into new geographic regions. The global market for diabetes treatments is substantial, estimated at over $100 billion annually. By securing regulatory approvals in key markets such as Europe and Asia, PharmaRoth Labs can significantly increase its revenue streams. This expansion requires strategic partnerships with local distributors and targeted marketing campaigns to reach potential customers. The timeline for this growth opportunity is estimated at 2-3 years, contingent on regulatory approvals and market entry strategies.
• Strategic Partnerships and Collaborations: PharmaRoth Labs, Inc. can pursue strategic partnerships with other healthcare companies and research institutions to enhance its product development and market access. Collaborations with established pharmaceutical companies can provide access to advanced research and development capabilities, while partnerships with healthcare providers can facilitate the integration of Sucanon into treatment protocols. These partnerships can also help PharmaRoth Labs expand its distribution network and reach a wider customer base. The timeline for securing strategic partnerships is estimated at 1-2 years, depending on the negotiation process and alignment of interests.
• Further Clinical Validation of Sucanon: PharmaRoth Labs, Inc. can invest in further clinical trials to validate the efficacy and safety of Sucanon. Conducting rigorous clinical studies and publishing the results in peer-reviewed journals can enhance the credibility of Sucanon and increase its acceptance among healthcare professionals and consumers. This validation can also support the company's marketing efforts and differentiate Sucanon from competing products. The timeline for completing clinical trials and publishing the results is estimated at 2-3 years, depending on the study design and regulatory requirements.
• Development of New Nutraceutical Products: PharmaRoth Labs, Inc. can leverage its expertise in herbal-based treatments to develop new nutraceutical products targeting other health conditions. Expanding its product portfolio can diversify its revenue streams and reduce its reliance on Sucanon. The company can focus on developing products that address unmet needs in the market and align with its core competencies. The timeline for developing and launching new nutraceutical products is estimated at 2-3 years, depending on the complexity of the product and regulatory requirements.
• Direct-to-Consumer Marketing and Sales: PharmaRoth Labs, Inc. can enhance its direct-to-consumer marketing and sales efforts to reach potential customers directly. Utilizing online advertising, social media marketing, and e-commerce platforms can increase brand awareness and drive sales. The company can also offer personalized consultations and educational resources to help customers make informed decisions about their health. The timeline for implementing and optimizing direct-to-consumer marketing strategies is ongoing, with continuous monitoring and adjustments based on performance data.

What Are ROTH's Competitive Advantages?

• Proprietary formulation of Sucanon, providing a unique herbal-based treatment for type-2 diabetes.
• Established brand recognition and customer loyalty in certain markets.
• Strategic partnerships with distributors and healthcare providers.

What Does ROTH Do?

PharmaRoth Labs, Inc., established in 2000 and headquartered in Las Vegas, Nevada, operates as a nutraceutical company with a focus on developing, marketing, and distributing herbal-based treatments. The company's flagship product is Sucanon, a nutraceutical designed for individuals with type-2 diabetes. Originally known as Fero Industries Inc., the company rebranded to PharmaRoth Labs, Inc. in March 2013, signaling a strategic shift towards the nutraceutical market. PharmaRoth Labs aims to provide alternative treatment options for managing diabetes through natural ingredients. The company's business model involves direct marketing and distribution of Sucanon to consumers across various global markets. PharmaRoth Labs competes with both pharmaceutical companies offering traditional diabetes medications and other nutraceutical firms providing alternative treatments. The company's success hinges on the efficacy and market acceptance of Sucanon, as well as its ability to navigate the regulatory landscape for nutraceutical products in different countries. The company's focus remains on expanding its market reach and enhancing its product offerings within the nutraceutical space.

What Products and Services Does ROTH Offer?

• Develops herbal-based nutraceutical treatments.
• Focuses on producing Sucanon, a treatment for type-2 diabetes.
• Markets Sucanon to consumers worldwide.
• Distributes Sucanon through various channels.
• Conducts research and development to improve its products.
• Seeks regulatory approvals for its products in different countries.
• Engages in strategic partnerships to expand its market reach.

How Does ROTH Make Money?

• Develops and manufactures Sucanon, an herbal-based nutraceutical treatment for type-2 diabetes.
• Markets and distributes Sucanon directly to consumers and through distributors.
• Generates revenue through the sale of Sucanon in various global markets.

What Industry Does ROTH Operate In?

PharmaRoth Labs, Inc. operates within the biotechnology industry, specifically focusing on the nutraceutical segment. The global nutraceutical market is experiencing growth driven by increasing consumer awareness of preventive healthcare and natural remedies. The competitive landscape includes established pharmaceutical companies and other nutraceutical firms. PharmaRoth Labs' success depends on its ability to differentiate Sucanon through clinical validation and effective marketing strategies. The company must also navigate the regulatory complexities associated with nutraceutical products in various global markets. The market size for diabetes treatments, including nutraceuticals, is substantial and growing, presenting both opportunities and challenges for PharmaRoth Labs.

Who Are ROTH's Key Customers?

• Individuals with type-2 diabetes seeking alternative treatment options.
• Healthcare providers who recommend or prescribe nutraceutical treatments.
• Distributors and retailers who sell nutraceutical products to consumers.

PharmaRoth Labs, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Return on equity for PharmaRoth Labs, Inc. stands at 17.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.1%, showing how much profit it generates from its asset base. A current ratio of 0.35 means current liabilities exceed short-term assets, a liquidity point worth watching.

Company Profile

PharmaRoth Labs, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Luis Manuel Ornelas Lopez. ROTH has traded publicly since 2009.

ROTH Financials

ROTH Latest News

No recent news available for ROTH.

ROTH Analyst Consensus

ROTH MoonshotScore

PharmaRoth Labs, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources